Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Arabi, Y. M., Gordon, A. C., & Investigators", ". R. Intensive Care Medicine, 47(8):867–886, August, 2021.
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial [link]Paper  doi  bibtex   
@article{arabi_lopinavir-ritonavir_2021,
	title = {Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with {COVID}-19: {REMAP}-{CAP} randomized controlled trial},
	volume = {47},
	issn = {0342-4642, 1432-1238},
	shorttitle = {Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with {COVID}-19},
	url = {https://link.springer.com/10.1007/s00134-021-06448-5},
	doi = {10.1007/s00134-021-06448-5},
	language = {en},
	number = {8},
	urldate = {2021-10-02},
	journal = {Intensive Care Medicine},
	author = {Arabi, Yaseen M. and Gordon, Anthony C. and "the REMAP-CAP Investigators"},
	month = aug,
	year = {2021},
	pages = {867--886},
}

Downloads: 0